November 10, 2026 · Radiology · DOI: 10.1148/radiol.253678

Low-Dose CT Lung-RADS 2022 for the Management of Screening- and Non-Screening-detected Lung Cancer Associated with Cystic Airspaces.

Listen to this summary

This secondary analysis of 1,258 participants from the NLST, ITALUNG, and LUSI trials examined whether lung cancers associated with cystic airspaces (CA) differ in outcomes from noncystic non-small cell lung cancer and whether Lung-RADS 2022 could enable earlier diagnosis. Seventy-three CA-associated cancers (about 6% of both screening- and non-screening-detected cancers) showed 5-year lung cancer-specific survival of 51.4%, similar to the 53.2% for noncystic NSCLC (subdistribution hazard ratio 1.15, P = .44). The authors found that Lung-RADS 2022 criteria for atypical cysts might have allowed earlier diagnosis in 75% of these cancers.

Mario Mascalchi, Edoardo Cavigli, Donella Puliti, Francisco Cortez Ibanez, Gianfranco Manneschi, Giuseppe Gorini, Giulia Picozzi, Giulia Raffaella De Luca, Lapo Sali, Stefano Diciotti, Stefan Delorme, Rudolf Kaaks

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play